Kestra Medical Technologies' Revenue Soars 51.5%, Net Loss Widens

TL;DR

**KMTS is burning cash fast despite strong revenue growth, making it a risky bet until they show a clear path to profitability.**

AI Summary

Kestra Medical Technologies, Ltd. (KMTS) reported a significant increase in revenue for the three months ended July 31, 2025, reaching $19.371 million, up from $12.782 million in the same period of 2024, representing a 51.5% increase. Despite this revenue growth, the company's net loss widened to $25.826 million for the three months ended July 31, 2025, compared to a net loss of $20.323 million in the prior year, primarily due to a substantial increase in selling, general, and administrative expenses, which surged to $33.728 million from $19.227 million. Cash and cash equivalents decreased to $201.214 million as of July 31, 2025, from $237.595 million on April 30, 2025. The company utilized $26.274 million in operating activities during the quarter, an increase from $17.499 million in the prior year. KMTS completed an IPO in March 2025, raising $215.789 million in proceeds, which management believes will fund operations for at least the next 12 months, despite an accumulated deficit of $546.075 million.

Why It Matters

Kestra Medical Technologies' substantial revenue growth of 51.5% indicates increasing market acceptance for its ASSURE WCD, which is crucial for a commercial-stage medical device company. However, the widening net loss and increased operating expenses, particularly in selling, general, and administrative, raise concerns about profitability and cost management. For investors, this mixed performance suggests a high-growth, high-burn scenario, typical for emerging medical tech, but demands close scrutiny of future expense control and path to profitability. The competitive landscape in wearable defibrillators is intense, and KMTS's ability to scale efficiently will determine its long-term viability and impact on patient care.

Risk Assessment

Risk Level: high — The company reported a net loss of $25.826 million for the three months ended July 31, 2025, and an accumulated deficit of $546.075 million. Cash used in operating activities increased to $26.274 million, indicating a significant cash burn rate despite the recent IPO proceeds of $215.789 million in March 2025.

Analyst Insight

Investors should monitor Kestra Medical Technologies' next few quarterly reports closely for signs of improved cost control and a narrowing net loss, particularly in selling, general, and administrative expenses. While revenue growth is strong, the current cash burn rate suggests a need for further capital raises if profitability isn't achieved within the next 12-18 months, potentially diluting existing shareholders.

Financial Highlights

debt To Equity

0.44

revenue

$19.371M

operating Margin

-149.1%

total Assets

$266.296M

total Debt

$41.486M

net Income

($25.826M)

eps

N/A

gross Margin

45.7%

cash Position

$201.214M

revenue Growth

+51.5%

Key Numbers

• $19.371M — Revenue (Increased from $12.782M in Q3 2024, a 51.5% increase)
• $25.826M — Net Loss (Widened from $20.323M in Q3 2024)
• $33.728M — Selling, General and Administrative Expenses (Increased from $19.227M in Q3 2024)
• $201.214M — Cash and Cash Equivalents (As of July 31, 2025, down from $237.595M on April 30, 2025)
• $26.274M — Cash Used in Operating Activities (For the three months ended July 31, 2025, up from $17.499M in Q3 2024)
• $546.075M — Accumulated Deficit (As of July 31, 2025)
• $215.789M — IPO Proceeds (Raised in March 2025 after deducting underwriting discounts)
• 51,449,053 — Common Shares Outstanding (As of September 11, 2025)

Key Players & Entities

• Kestra Medical Technologies, Ltd. (company) — Registrant and medical device company
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Stock Market LLC (company) — Exchange where KMTS common shares are registered
• West Affum Holdings, L.P. (company) — Former parent company of Kestra Medical Technologies, Ltd.
• ASSURE WCD (company) — Wearable Cardioverter Defibrillator product
• U.S. Food and Drug Administration (regulator) — Approved the ASSURE WCD in July 2021
• Kirkland, WA (person) — Location of principal executive offices
• Bermuda (person) — Jurisdiction of incorporation

FAQ

Risk Factors

• Significant increase in SG&A expenses impacting net loss [high — financial]: Selling, general, and administrative expenses surged by 75.4% to $33.728 million in the three months ended July 31, 2025, from $19.227 million in the prior year. This substantial increase outpaced revenue growth and contributed significantly to the widening net loss of $25.826 million.
• Negative operating cash flow and declining cash reserves [high — financial]: The company used $26.274 million in operating activities during the quarter ended July 31, 2025, an increase from $17.499 million in the prior year. Cash and cash equivalents decreased by $36.381 million to $201.214 million, raising concerns about near-term liquidity despite IPO proceeds.
• Substantial accumulated deficit [high — financial]: Kestra Medical Technologies has an accumulated deficit of $546.075 million as of July 31, 2025. While the IPO proceeds are expected to fund operations for at least 12 months, the significant deficit highlights a history of unprofitability.
• Dependence on successful product development and market adoption [medium — operational]: As a medical technology company, Kestra's success hinges on the development, regulatory approval, and market acceptance of its products. Any delays or failures in these areas could materially impact revenue and financial performance.
• Navigating complex medical device regulations [medium — regulatory]: The medical technology industry is subject to stringent regulatory oversight from bodies like the FDA. Compliance with these regulations is critical and can be costly and time-consuming, with potential for significant penalties for non-compliance.

Industry Context

The medical technology industry is characterized by rapid innovation, significant R&D investment, and a complex regulatory landscape. Companies like Kestra Medical Technologies compete on technological advancement, clinical efficacy, and market access. The sector is driven by an aging global population, increasing demand for advanced healthcare solutions, and evolving reimbursement policies.

Regulatory Implications

Kestra Medical Technologies operates in a highly regulated environment, requiring adherence to stringent standards from bodies such as the FDA. Compliance with these regulations is critical for product approval and market access, and any failures can lead to significant delays, costs, and reputational damage.

What Investors Should Do

1. Monitor SG&A expense growth closely: Investors should scrutinize future SG&A spending to ensure it is aligned with sustainable growth and not solely contributing to widening losses.
2. Evaluate cash burn rate and runway: With cash used in operations increasing, investors need to assess the company's cash runway and the sufficiency of the IPO proceeds to achieve profitability.
3. Assess path to profitability: Given the substantial accumulated deficit and increasing net losses, investors should look for clear strategies and milestones that demonstrate a credible path to profitability.
4. Analyze revenue drivers: Understand the specific products or services contributing to the 51.5% revenue growth and their sustainability.

Key Dates

• 2025-07-31: End of Q3 2025 reporting period — Indicates significant revenue growth but also a widening net loss and increased cash burn.
• 2025-04-30: End of Q2 2025 reporting period — Represents the prior quarter's financial position, showing a higher cash balance before the current quarter's utilization.
• 2025-03-01: Initial Public Offering (IPO) — Raised $215.789 million, providing capital to fund operations, but also highlighting the company's need for external funding due to its accumulated deficit.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. It represents a negative balance in retained earnings. (Indicates that Kestra Medical Technologies has historically incurred more expenses than revenues, requiring significant external funding like its recent IPO.)

Selling, general and administrative expenses (SG&A)

Costs incurred by a company for marketing, advertising, sales, and administrative functions, excluding research and development and cost of goods sold. (The substantial increase in SG&A is a primary driver of the company's widening net loss, despite strong revenue growth.)

Cash used in operating activities

The net amount of cash spent by a company to fund its core business operations during a specific period. (An increase in cash used in operations signifies a higher burn rate, which is a key concern for investors given the company's net losses.)

IPO Proceeds

The total amount of money raised by a company through an Initial Public Offering, after deducting underwriting discounts and commissions. (This capital is crucial for Kestra's continued operations and growth, especially given its accumulated deficit and ongoing operating losses.)

Year-Over-Year Comparison

Compared to the prior year's three-month period, Kestra Medical Technologies demonstrated robust revenue growth of 51.5%, increasing from $12.782 million to $19.371 million. However, this top-line expansion was overshadowed by a significant increase in operating expenses, particularly SG&A, which grew by 75.4%. This led to a wider net loss of $25.826 million, up from $20.323 million. Cash reserves also declined, and cash used in operations increased, indicating a worsening cash burn despite the revenue surge.

Key Financial Figures

• $1.00 — h registered Common Shares, par value $1.00 per share KMTS The Nasdaq Stock Mar
• $0.01 — Intermediate Holdings at a par value of $0.01 prior to the IPO has been retrospective

Filing Documents

• ck0001877184-20250731.htm (10-Q) — 1576KB
• ck0001877184-ex31_1.htm (EX-31.1) — 18KB
• ck0001877184-ex31_2.htm (EX-31.2) — 18KB
• ck0001877184-ex32_1.htm (EX-32.1) — 10KB
• ck0001877184-ex32_2.htm (EX-32.2) — 10KB
• 0000950170-25-114536.txt ( ) — 7608KB
• ck0001877184-20250731.xsd (EX-101.SCH) — 1289KB
• ck0001877184-20250731_htm.xml (XML) — 1155KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28 PART II. OTHER INFORMATION 31 Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosures 31 Item 5. Other Information 31 Item 6. Exhibits 32

Signatures

Signatures 33 1 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the "Quarterly Report") contains "forward-looking" statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained principally in the section captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations." Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, technology developments, financing and investment plans, dividend policy, competitive position, industry and regulatory environment, potential growth opportunities and the effects of competition. Forward looking statements include statements that are not historical facts and can be identified by terms such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "will" and "would," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from our expectations are described in Part II, Item 1A, "Risk Factors" and elsewhere in this Quarterly Report, and include, but are not limited to, the following: our ability to continue to expand the commercialization of our ASSURE WCD, including associated

– Financial Information

Part I – Financial Information

Financial Statements

Item 1. Financial Statements. KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) (unaudited) July 31, April 30, 2025 2025 Assets Current assets Cash and cash equivalents $ 201,214 $ 237,595 Accounts receivable, net 9,246 8,081 Disposable medical equipment supplies 6,802 6,572 Prepaid expenses and other current assets 3,429 3,080 Total current assets 220,691 255,328 Right-of-use assets 2,046 2,078 Deposits 1,787 2,021 Restricted cash 334 334 Property and equipment, net 40,376 34,830 Other long-term assets 1,062 1,153 Total assets $ 266,296 $ 295,744 Liabilities and Shareholders' Equity Current liabilities Accounts payable $ 18,570 $ 23,961 Accrued liabilities 13,650 13,829 Operating lease liabilities, current portion 36 187 Total current liabilities 32,256 37,977 Operating lease liabilities, net of current portion 3,067 3,026 Warrant liabilities 5,188 8,097 Other long-term liabilities 140 140 Long-term debt, net 41,486 41,098 Total liabilities 82,137 90,338 Commitments and contingencies (Note 14) Shareholders' equity Common shares, $ 1.00 par value; 100,000,000 shares authorized as of July 31, 2025 and April 30, 2025; 51,348,656 shares issued and outstanding as of July 31, 2025 and April 30, 2025 51,349 51,349 Additional paid-in capital 678,885 674,306 Accumulated deficit ( 546,075 ) ( 520,249 ) Total shareholders' equity 184,159 205,406 Total liabilities and shareholders' equity $ 266,296 $ 295,744 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share amounts) (unaud

View Full Filing

View this 10-Q filing on SEC EDGAR